<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148013">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01940887</url>
  </required_header>
  <id_info>
    <org_study_id>OPH1004</org_study_id>
    <nct_id>NCT01940887</nct_id>
  </id_info>
  <brief_title>A Phase 3 Safety and Efficacy Study of Fovista™ (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy</brief_title>
  <official_title>A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista™ (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ophthotech Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ophthotech Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the safety and efficacy  of  intravitreal
      administration of Fovista™  administered in combination with either Avastin® or Eylea®
      compared to Avastin®   or Eylea® monotherapy in subjects with subfoveal choroidal
      neovascularization secondary to age-related macular degeneration (AMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized in a 1:1 ratio to the following dose groups:

        -  Fovista™ 1.5 mg/eye + Avastin® 1.25 mg/eye or Eylea® 2 mg/eye

        -  Fovista™ sham + Avastin® 1.25 mg/eye or Eylea® 2 mg/eye

      Subjects will be treated for a total of 24 months with active Fovista™ or sham in
      combination with either Avastin® or Eylea® with the primary endpoint at 12 months.

      Primary Efficacy Endpoint:

      The primary efficacy endpoint is the mean change in visual acuity (ETDRS letters) from
      baseline at the month 12 visit.

      Safety Endpoints:

      Safety endpoints include adverse events, vital signs, ophthalmic variables [ophthalmic
      examination, intraocular pressure (IOP), fluorescein angiogram (FA), optical coherence
      tomography (OCT)], ECG, and laboratory variables.

      Approximately 622 subjects will be randomized into one of the two treatment cohorts (311
      patients per dose group).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean change in visual acuity from baseline at the Month 12 visit.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary efficacy endpoint is the mean change in visual acuity (ETDRS letters) from baseline at the month 12 visit.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">622</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>E10030 + bevacizumab or aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E10030 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham + bevacizumab or aflibercept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>E10030 sham intravitreal injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E10030</intervention_name>
    <arm_group_label>E10030 + bevacizumab or aflibercept</arm_group_label>
    <other_name>Fovista™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab  or  aflibercept</intervention_name>
    <description>Patients are randomized to receive either bevacizumab or aflibercept</description>
    <arm_group_label>E10030 + bevacizumab or aflibercept</arm_group_label>
    <arm_group_label>Sham + bevacizumab or aflibercept</arm_group_label>
    <other_name>Avastin®</other_name>
    <other_name>Eylea®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E10030 sham intravitreal injection</intervention_name>
    <description>Pressure on the eye with a syringe with no needle</description>
    <arm_group_label>Sham + bevacizumab or aflibercept</arm_group_label>
    <other_name>Sham</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of either gender aged ≥ 50 years

          -  Subfoveal choroidal neovascularization (CNV) due to AMD with some classic component

        Exclusion Criteria:

          -  Any prior treatment for AMD in the study eye prior to the Day 1 visit, except oral
             supplements of vitamins and minerals.

          -  Any prior intravitreal treatment in the study eye prior to the Day 1 visit,
             regardless of indication (including intravitreal corticosteroids).

          -  Any intraocular surgery or thermal laser within three (3) months of trial entry. Any
             prior thermal laser in the macular region, regardless of indication.

          -  Subjects with subfoveal scar or subfoveal atrophy are excluded

          -  Diabetes mellitus
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karen Lewis</last_name>
    <phone>212-845-8223</phone>
    <email>Karen.Lewis@ophthotech.com</email>
  </overall_contact>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 19, 2013</lastchanged_date>
  <firstreceived_date>September 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wet AMD</keyword>
  <keyword>choroidal neovascularization</keyword>
  <keyword>Fovista™</keyword>
  <keyword>E10030</keyword>
  <keyword>Avastin®</keyword>
  <keyword>Eylea®</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
